Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Seeks Eye Care Leadership With Full, $50 Billion Alcon Takeover

This article was originally published in The Gray Sheet

Executive Summary

In a strong sign of Novartis' long-term commitment to ophthalmology, the firm announced Jan. 4 that it would exercise its option to purchase Nestlé's remaining 52% stake in eye-care group Alcon for $28.1 billion and separately pursue a buyout of the 23% of shares owned by independent stockholders

You may also be interested in...



With 100% Alcon Ownership, Novartis Forms New Eye Care Unit

Novartis will create a new eye care division – representing the fifth growth platform in its health care portfolio – after acquiring full ownership of ophthalmology specialist Alcon.

With 100% Alcon Ownership, Novartis Forms New Eye Care Unit

Novartis will create a new eye care division – representing the fifth growth platform in its health care portfolio – after acquiring full ownership of ophthalmology specialist Alcon.

As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?

Independent Alcon shareholders have been holding out for months for a buyout offer from Novartis that is closer to what the latter firm is paying for the majority of the company

Related Content

Topics

UsernamePublicRestriction

Register

MT028360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel